Board of Directors

Board of Directors



Warren HuffFounding Chief Executive Officer and President


Warren is the Chairman, Chief Executive Officer and President of Reata Pharmaceuticals. He has served as our sole CEO, President, and as Chairman of the board of directors since our founding in 2002. Prior to founding Reata, Warren served as CEO in a number of health care and information technology start-up enterprises. Warren started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. He received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University Dedman School of Law.

James BassTrinity Summits, LLC


James has served as a member of the Board of Directors since July 2004. James is a member of the Board of Managers of Snowbird Holdings, LLC and Trinity Summits, LLC. For the past 5 years, he has been managing family assets and investments as his primary business activity. He previously served as an executive director of FB Gemini Limited, an Asian regional investment bank based in Hong Kong, prior to which he was an associate attorney and later partner at Gibson, Dunn & Crutcher LLP. He graduated with a B.A. degree from Yale University and obtained his J.D. degree from Stanford University.

R. Kent McGaughy, Jr.CPMG, Inc.


Kent has served as a member of the Board of Directors since December 2004 Mr. McGaughy is a partner in CPMG, Inc. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Inc. in 1997, he worked in mergers and acquisitions at Simmons & Company International. He currently serves on the boards of several private companies. Mr. McGaughy received his B.A. from The University of Texas (summa cum laude and member of Phi Beta Kappa) and his M.B.A. from Harvard Business School.

Jack B. NielsenNovo Ventures


Jack has served as a member of the Board of Directors since June 2006. Jack has worked within the Novo A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Jack was employed as a Partner at Novo Ventures (US) Inc. in San Francisco, where he established the office that provides certain consultancy services to Novo A/S. He served on the board of directors of publicly traded companies Akebia Therapeutics, Inc. from 2013 to June 2015 and Merus B.V. from 2015 to present. He is also currently a member of the board of directors of a number of private companies. He received a M.Sc. in Chemical Engineering from the Technical University in Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management; Technical University of Denmark.

William E. RoseMontrose Capital, Inc.


William has served as a member of the Board of Directors since February 2016. He is the President of Montrose Capital, Inc. Prior to Montrose, William was associated with HBK Capital Management from 1991 until 2012, serving in various capacities, including Co-Chief Investment Officer. He currently serves as the Chairman of the Board of Trustees for Greenhill School, and is also a member of the Investment Committee for the Dallas Museum of Art. William received a B.A. in Political Science from Duke University in 1989.


Dennis Stone, M.D.


Dennis has served as a member of the Board of Directors since September 2002. Until his retirement, from August 2011 until June 2016, he was Chief Scientific Officer of Remeditex Ventures LLC. He joined Remeditex in August 2011 from UT Southwestern Medical Center, where he was Professor of Internal Medicine, Physiology, and Biochemistry. He served as the Vice President of Technology Development for UT Southwestern from 1998 until July 2011. Dr. Stone has served on the board of directors of Eliance Biotechnologies, Inc., Myogen, Inc., miRagen Therapeutics, Inc., and MacroGenics, Inc. In addition, he served as the Chairman of the UT Regents’ Technology Transfer Commission, and he was vice chairman of the board of the Texas Emerging Technology Fund’s Life Science Commercialization Center. Dr. Stone received his undergraduate training at The University of Texas at Austin and his medical degree from UT Southwestern.